Short-acting bronchodilators are the first-line therapy, which is widely used in bronchodilators. These agents have a short-term (2-4 hours) duration of action and therefore require multiple dosages. Whereas, long-acting bronchodilators, which are introduced recently, have an extended period of action. They reduce the process of multiple dosages. Therefore, they are more effective than the short-term bronchodilators.

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Market outline

PART 05: Pipeline analysis

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Market segmentation by drug class

Anticholinergic bronchodilators

Adrenergic bronchodilators

Bronchodilator combinations

Methylxanthines

PART 08: Geographical segmentation

Bronchodilators market in Americas

Bronchodilators market in EMEA

Bronchodilators market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges

Market drivers

Market challenges

PART 11: Market trends

Innovative technologies for drug delivery

Growing usage of home healthcare devices

Strong product pipeline

PART 12: Vendor landscape

Competitive scenario

PART 13: Key vendor analysis

AstraZeneca

Boehringer Ingelheim

F. Hoffmann-La Roche

GlaxoSmithKline

Other prominent vendors

PART 14: Appendix

List of abbreviations

PART 15: Explore Technavio